Published in the Journal of Clinical Oncology

New data continues to lend support to the increasing role of biomarker analysis and molecular profiling in cancer diagnosis and treatment. A study, published in the Journal of Clinical Oncology, confirmed that there are FDA-approved agents with literature support that can successfully be used against targets in refractory tumors, improving outcomes in cancers where no standard-of-care options exists:

• Overall improvement in progression-free survival (PFS), using molecular profiling to guide therapy, was seen in 27% of patients.
• Patients with a PFS ratio of ≥1.3 had better survival than the total population, suggesting the outcomes were significant, durable and impacted overall survival in a very sick patient population.

1. Von Hoff, D., et al. Pilot Study Using Molecular Profiling of Patient’s Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. J Clin Oncol. 20;28(33):4877-83. Epub 2010 Oct 4.

Caris Target Now was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. It has not been approved by the United States Food and Drug Administration.